SparingVision announces strategic collaboration with Intellia Therapeutics

4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

Orchard Therapeutics Receives EC Approval for Treatment of Early-Onset Metachromatic Leukodystrophy

ADC Therapeutics Announces FDA’s Acceptance of its Biologics License Application

4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million